Medzinische Universität Innsbruck
Welcome,         Profile    Billing    Logout  
 4 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Galle, Peter R
ABC-HCC, NCT04803994 / 2020-004210-35: The Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma

Recruiting
3
434
Europe, Japan
Atezolizumab, Tecentriq, Bevacizumab, Avastin, TACE, transarterial chemoembolization
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, F. Hoffmann-La Roche Ltd
Hepatocellular Carcinoma
04/25
04/25
RENOTACE, NCT04777851: Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7

Recruiting
3
496
Europe, Japan, US, RoW
Regorafenib in combination with pembrolizumab, Stivarga® (regorafenib), Keytruda® (pembrolizumab), Loco-regional therapy, Convention transarterial chemoembolization (cTACE), Drug-eluting bead transarterial chemoembolization (DEB-TACE), Transarterial Chemoembolization (TACE), Transarterial radioembolization (TARE)
Translational Research in Oncology, Bayer
Carcinoma, Hepatocellular
10/25
04/27
NCT05733598: RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Not yet recruiting
2
60
Europe, US
RP3, atezolizumab, bevacizumab
Replimune Inc., Roche Pharma AG
Locally Advanced Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
04/27
07/27
JADE, NCT04510740: Liver Cancer Registry Platform

Recruiting
N/A
1000
Europe
Physician's choice according to patient's needs.
iOMEDICO AG
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
12/26
12/26

Download Options